NEJM This Week — April 9, 2026

This week's episode of NEJM This Week highlights groundbreaking research and clinical insights across multiple domains of medicine. Key findings include a South Korean trial demonstrating that intensive LDL cholesterol targeting (below 55 mg/dL) significantly reduces cardiovascular events in patients with atherosclerotic cardiovascular disease compared to conventional targets (below 70 mg/dL), supporting current international guidelines. A multifaceted team-based strategy for hypertension control in low-income patients across federally qualified health centers in Louisiana and Mississippi led to significantly greater blood pressure reductions, offering a scalable model for addressing health disparities. Novel therapies are advancing in immune and oncologic diseases: mesogitimab shows promise in treating refractory immune thrombocytopenia, and setidagrasib, a first-in-class KRAS G12D-targeted degrader, demonstrates anti-tumor activity in advanced lung and pancreatic cancers. The episode also features a compelling case of a rare post-catheter ablation complication—esophageal pericardial fistula—highlighting the importance of vigilance in post-procedural care. Perspectives explore systemic inequities, including the impact of immigration enforcement on children’s health, the role of community-school data partnerships in advancing health equity, and the urgent need to integrate anti-racism pedagogy into medical education. A review of celiac disease underscores diagnostic challenges and the risks of non-adherence to gluten-free diets, while a clinical implications article calls for rigorous, long-term trials to establish evidence-based dietary interventions in oncology. The episode concludes with two striking clinical images: necrolytic migratory erythema due to a glucagonoma and silent aspiration following prolonged intubation.